Levofolene

Levoleucovorin, the active ingredient in Levofolene, is a folate analog presented as an injectable solution for intravenous use. It is employed to rescue patients from high‑dose methotrexate toxicity, to augment 5‑fluorouracil chemotherapy, and to prevent or treat folate deficiency in oncology settings.

GNH USA supplies Levofolene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable global distribution.

Levofolene is used in oncology and supportive care to address folate‑related pathways.

- High‑dose methotrexate rescue: restores DNA synthesis and reduces toxicity after methotrexate therapy. - 5‑fluorouracil enhancement: stabilizes the drug‑enzyme complex to improve antitumor effect. - Folate deficiency prevention/treatment: supplies reduced folate to patients at risk of deficiency.

Levofolene may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis following infusion. - Rash: transient erythematous skin changes. - Headache: mild headache during or after administration.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Renal dysfunction: acute kidney injury in susceptible patients. - Hepatic toxicity: elevated liver enzymes or hepatic failure in rare cases.

Before initiating Levofolene therapy, consider the following precautions.

- Renal function monitoring: assess creatinine clearance and adjust use in renal impairment. - Hepatic function monitoring: evaluate liver enzymes and avoid use in severe hepatic disease. - Known hypersensitivity: discontinue if allergic reactions occur. - Pregnancy considerations: use only if potential benefit justifies potential risk to the fetus. - Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Levofolene can interact with several agents; awareness of the interaction level is essential.

Major Interactions (Avoid): - High‑dose methotrexate (improper timing): may increase toxicity if rescue is not correctly timed. - Pemetrexed (concurrent use): may diminish antitumor activity.

Moderate Interactions (Monitor Closely): - 5‑Fluorouracil (combined therapy): monitor for enhanced cytotoxicity. - Corticosteroids (long‑term use): may alter folate metabolism. - NSAIDs (renal clearance): observe renal function closely.